{"entity":{"type":"insider","cik":"0001708269","url":"/insider/0001708269","json_url":"/insider/0001708269.json","name":"Atlas Venture Fund XI, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":47,"n_filings":13,"first":"2019-06-25","last":"2025-02-10","span_basis":"filed_date"},"name_variants":[{"name":"Atlas Venture Fund XI, L.P.","source":"filing","n_filings":13,"first_seen":"2019-06-25","last_seen":"2025-02-10"}],"transactions":[{"id":4711190,"accession":"0000950170-25-017030","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-017030","line_url":"/filing/0000950170-25-017030#line-3","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Sionna Therapeutics, Inc.","issuer_ticker":"SION","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Opportunity Fund II, L.P.","owner_display_name":"Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60000.0,"shares_display":"60,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":1080000.0,"total_display":"1,080,000.00","total_whole":"1,080,000","shares_owned_after":807727.0,"shares_owned_after_display":"807,727","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-02-10","filed_date":"2025-02-10","scope":"insider"},{"id":2928271,"accession":"0001415889-24-005777","txn_seq":18,"anchor":"line-18","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_display_name":"Atlas Venture Associates XI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":190920.0,"shares_display":"190,920","price_per_share":24.836599622878694,"price_display":"24.84","price_state":"stated","total_value":4741803.6,"total_display":"4,741,803.60","total_whole":"4,741,804","shares_owned_after":5700521.0,"shares_owned_after_display":"5,700,521","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-28","filed_date":"2024-02-28","scope":"insider","n_lines":6},{"id":2928249,"accession":"0001415889-24-005777","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_display_name":"Atlas Venture Associates XI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":368699.0,"shares_display":"368,699","price_per_share":24.405887783801962,"price_display":"24.41","price_state":"stated","total_value":8998426.42,"total_display":"8,998,426.42","total_whole":"8,998,426","shares_owned_after":5878544.0,"shares_owned_after_display":"5,878,544","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-28","scope":"insider","n_lines":6},{"id":2928222,"accession":"0001415889-24-005777","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_display_name":"Atlas Venture Associates XI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":248219.0,"shares_display":"248,219","price_per_share":23.715642033849143,"price_display":"23.72","price_state":"stated","total_value":5886672.95,"total_display":"5,886,672.95","total_whole":"5,886,673","shares_owned_after":6216250.0,"shares_owned_after_display":"6,216,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-26","filed_date":"2024-02-28","scope":"insider","n_lines":6},{"id":2659297,"accession":"0001415889-24-005124","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-005124","line_url":"/filing/0001415889-24-005124","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.","owner_display_name":"Atlas Venture Opportunity Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":196928.0,"shares_display":"196,928","price_per_share":22.7,"price_display":"22.70","price_state":"stated","total_value":4470265.6,"total_display":"4,470,265.60","total_whole":"4,470,266","shares_owned_after":6352562.0,"shares_owned_after_display":"6,352,562","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-23","filed_date":"2024-02-23","scope":"insider","n_lines":3},{"id":2659279,"accession":"0001415889-24-005124","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-005124","line_url":"/filing/0001415889-24-005124#line-3","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.","owner_display_name":"Atlas Venture Opportunity Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":119360.0,"shares_display":"119,360","price_per_share":22.66,"price_display":"22.66","price_state":"stated","total_value":2704697.6,"total_display":"2,704,697.60","total_whole":"2,704,698","shares_owned_after":6512104.0,"shares_owned_after_display":"6,512,104","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-22","filed_date":"2024-02-23","scope":"insider"},{"id":2659275,"accession":"0001415889-24-005124","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-005124","line_url":"/filing/0001415889-24-005124","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.","owner_display_name":"Atlas Venture Opportunity Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":184501.0,"shares_display":"184,501","price_per_share":22.573412827030747,"price_display":"22.57","price_state":"stated","total_value":4164817.24,"total_display":"4,164,817.24","total_whole":"4,164,817","shares_owned_after":6666628.0,"shares_owned_after_display":"6,666,628","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-21","filed_date":"2024-02-23","scope":"insider","n_lines":2},{"id":2595350,"accession":"0001415889-24-004467","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001415889-24-004467","line_url":"/filing/0001415889-24-004467","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC","owner_display_name":"Atlas Venture Associates XI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":169539.0,"shares_display":"169,539","price_per_share":22.724285208713038,"price_display":"22.72","price_state":"stated","total_value":3852652.59,"total_display":"3,852,652.59","total_whole":"3,852,653","shares_owned_after":6819475.0,"shares_owned_after_display":"6,819,475","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-20","filed_date":"2024-02-20","scope":"insider","n_lines":2},{"id":2595339,"accession":"0001415889-24-004467","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-004467","line_url":"/filing/0001415889-24-004467#line-3","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC","owner_display_name":"Atlas Venture Associates XI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":162707.0,"shares_display":"162,707","price_per_share":23.14,"price_display":"23.14","price_state":"stated","total_value":3765039.98,"total_display":"3,765,039.98","total_whole":"3,765,040","shares_owned_after":6985504.0,"shares_owned_after_display":"6,985,504","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-16","filed_date":"2024-02-20","scope":"insider"},{"id":2595334,"accession":"0001415889-24-004467","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-004467","line_url":"/filing/0001415889-24-004467","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC","owner_display_name":"Atlas Venture Associates XI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":177906.0,"shares_display":"177,906","price_per_share":23.886769923442717,"price_display":"23.89","price_state":"stated","total_value":4249599.69,"total_display":"4,249,599.69","total_whole":"4,249,600","shares_owned_after":7150324.0,"shares_owned_after_display":"7,150,324","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-15","filed_date":"2024-02-20","scope":"insider","n_lines":2},{"id":2698180,"accession":"0001209191-24-003031","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-003031","line_url":"/filing/0001209191-24-003031","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates XI, LLC","owner_display_name":"Atlas Venture Opportunity Fund I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":0.64,"price_display":"0.64","price_state":"stated","total_value":640.0,"total_display":"640.00","total_whole":"640","shares_owned_after":2019563.0,"shares_owned_after_display":"2,019,563","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-08","filed_date":"2024-02-09","scope":"insider","n_lines":2},{"id":2981676,"accession":"0001209191-24-001655","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-24-001655","line_url":"/filing/0001209191-24-001655","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_display_name":"Atlas Venture Associates XI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2100.0,"shares_display":"2,100","price_per_share":0.83,"price_display":"0.83","price_state":"stated","total_value":1743.0,"total_display":"1,743.00","total_whole":"1,743","shares_owned_after":2020296.0,"shares_owned_after_display":"2,020,296","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-12","filed_date":"2024-01-16","scope":"insider","n_lines":2},{"id":2981664,"accession":"0001209191-24-001655","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-001655","line_url":"/filing/0001209191-24-001655","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_display_name":"Atlas Venture Associates XI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2135.0,"shares_display":"2,135","price_per_share":0.87,"price_display":"0.87","price_state":"stated","total_value":1857.45,"total_display":"1,857.45","total_whole":"1,857","shares_owned_after":2021836.0,"shares_owned_after_display":"2,021,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-11","filed_date":"2024-01-16","scope":"insider","n_lines":2},{"id":6957975,"accession":"0001209191-22-061243","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-061243","line_url":"/filing/0001209191-22-061243#line-1","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.","owner_display_name":"Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":934581.0,"shares_display":"934,581","price_per_share":10.7,"price_display":"10.70","price_state":"stated","total_value":10000016.7,"total_display":"10,000,016.70","total_whole":"10,000,017","shares_owned_after":934581.0,"shares_owned_after_display":"934,581","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-12","filed_date":"2022-12-14","scope":"insider"},{"id":6613397,"accession":"0001209191-22-050535","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-22-050535","line_url":"/filing/0001209191-22-050535#line-3","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Third Harmonic Bio, Inc.","issuer_ticker":"THRD","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates XI, LLC","owner_display_name":"Atlas Venture Opportunity Fund I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":5100000.0,"total_display":"5,100,000.00","total_whole":"5,100,000","shares_owned_after":10313763.0,"shares_owned_after_display":"10,313,763","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-19","filed_date":"2022-09-19","scope":"insider"},{"id":6699290,"accession":"0001209191-22-038713","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-038713","line_url":"/filing/0001209191-22-038713#line-1","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Day One Biopharmaceuticals, Inc.","issuer_ticker":"DAWN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity I, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, LLC","owner_display_name":"Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":766667.0,"shares_display":"766,667","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":11500005.0,"total_display":"11,500,005.00","total_whole":"11,500,005","shares_owned_after":766667.0,"shares_owned_after_display":"766,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-17","filed_date":"2022-06-22","scope":"insider"},{"id":4679419,"accession":"0001209191-21-069644","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-069644","line_url":"/filing/0001209191-21-069644#line-4","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Ikena Oncology, Inc.","issuer_ticker":"IKNA","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, LLC; Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Fund XI, L.P.","owner_display_name":"Atlas Venture Associates XI, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5959.0,"shares_display":"5,959","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":83426.0,"total_display":"83,426.00","total_whole":"83,426","shares_owned_after":1241935.0,"shares_owned_after_display":"1,241,935","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-14","filed_date":"2021-12-14","scope":"insider"},{"id":4679414,"accession":"0001209191-21-069644","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-069644","line_url":"/filing/0001209191-21-069644#line-3","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Ikena Oncology, Inc.","issuer_ticker":"IKNA","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, LLC; Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Fund XI, L.P.","owner_display_name":"Atlas Venture Associates XI, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8330.0,"shares_display":"8,330","price_per_share":14.64,"price_display":"14.64","price_state":"stated","total_value":121951.2,"total_display":"121,951.20","total_whole":"121,951","shares_owned_after":1247894.0,"shares_owned_after_display":"1,247,894","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-13","filed_date":"2021-12-14","scope":"insider"},{"id":4679410,"accession":"0001209191-21-069644","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-069644","line_url":"/filing/0001209191-21-069644#line-2","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Ikena Oncology, Inc.","issuer_ticker":"IKNA","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, LLC; Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Fund XI, L.P.","owner_display_name":"Atlas Venture Associates XI, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11989.0,"shares_display":"11,989","price_per_share":15.03,"price_display":"15.03","price_state":"stated","total_value":180194.67,"total_display":"180,194.67","total_whole":"180,195","shares_owned_after":1256224.0,"shares_owned_after_display":"1,256,224","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-10","filed_date":"2021-12-14","scope":"insider"},{"id":5282522,"accession":"0001104659-21-130026","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-21-130026","line_url":"/filing/0001104659-21-130026#line-4","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Fund XI, L.P.","owner_display_name":"Atlas Venture Opportunity Fund I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":187500.0,"shares_display":"187,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","total_whole":"3,000,000","shares_owned_after":735942.0,"shares_owned_after_display":"735,942","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-10-26","filed_date":"2021-10-26","scope":"insider"},{"id":4483859,"accession":"0001209191-21-037402","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-037402","line_url":"/filing/0001209191-21-037402","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Day One Biopharmaceuticals, Inc.","issuer_ticker":"DAWN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity I, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC","owner_display_name":"Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":8000000.0,"total_display":"8,000,000.00","total_whole":"8,000,000","shares_owned_after":250000.0,"shares_owned_after_display":"250,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-01","filed_date":"2021-06-02","scope":"insider","n_lines":2},{"id":4679403,"accession":"0001209191-21-069644","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-069644","line_url":"/filing/0001209191-21-069644#line-1","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Ikena Oncology, Inc.","issuer_ticker":"IKNA","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, LLC; Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Fund XI, L.P.","owner_display_name":"Atlas Venture Associates XI, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":125000.0,"shares_display":"125,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":2000000.0,"total_display":"2,000,000.00","total_whole":"2,000,000","shares_owned_after":874634.0,"shares_owned_after_display":"874,634","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-03-30","filed_date":"2021-12-14","scope":"insider"},{"id":8417175,"accession":"0001104659-19-037461","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-19-037461","line_url":"/filing/0001104659-19-037461#line-3","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Fund XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund I, L.P.","owner_display_name":"Atlas Venture Fund XI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":270000.0,"shares_display":"270,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":4320000.0,"total_display":"4,320,000.00","total_whole":"4,320,000","shares_owned_after":505099.0,"shares_owned_after_display":"505,099","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-24","filed_date":"2019-06-25","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0002036042","name":"Sionna Therapeutics, Inc.","url":"/issuer/0002036042","role":"Ten percent owner","n_filings":1,"first_seen":"2025-02-10","last_seen":"2025-02-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001818794","name":"Dyne Therapeutics, Inc.","url":"/issuer/0001818794","role":"Ten percent owner","n_filings":4,"first_seen":"2022-12-14","last_seen":"2024-02-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001840233","name":"Xilio Therapeutics, Inc.","url":"/issuer/0001840233","role":"Ten percent owner","n_filings":3,"first_seen":"2021-10-26","last_seen":"2024-02-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001923840","name":"Third Harmonic Bio, Inc.","url":"/issuer/0001923840","role":"Ten percent owner","n_filings":1,"first_seen":"2022-09-19","last_seen":"2022-09-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001845337","name":"Day One Biopharmaceuticals, Inc.","url":"/issuer/0001845337","role":"Ten percent owner","n_filings":2,"first_seen":"2021-06-02","last_seen":"2022-06-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001835579","name":"Ikena Oncology, Inc.","url":"/issuer/0001835579","role":"Ten percent owner","n_filings":1,"first_seen":"2021-12-14","last_seen":"2021-12-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001744659","name":"Akero Therapeutics, Inc.","url":"/issuer/0001744659","role":"Ten percent owner","n_filings":1,"first_seen":"2019-06-25","last_seen":"2019-06-25"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001708269","retrieved_at":"2026-08-22T09:14:21+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}